{
  "id": "54e1bdacae9738404b000009",
  "type": "factoid",
  "question": "What is generic name of drug Adempas?",
  "ideal_answer": "Riociguat is generic name of drug Adempas. It is a soluble guanylate cyclase stimulator that was approved for the treatment of patients with chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/24218053",
    "http://www.ncbi.nlm.nih.gov/pubmed/25395817",
    "http://www.ncbi.nlm.nih.gov/pubmed/25352393",
    "http://www.ncbi.nlm.nih.gov/pubmed/24391396",
    "http://www.ncbi.nlm.nih.gov/pubmed/24524094"
  ],
  "snippets": [
    {
      "text": "Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25395817",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Riociguat (Adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25395817",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Riociguat (Adempas(\u00ae)), a soluble guanylate cyclase stimulator, is a new, first-in-class drug approved for the treatment of patients with chronic thromboembolic pulmonary hypertension (CTEPH) [inoperable or persistent/recurrent following surgery] or pulmonary arterial hypertension (PAH). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25352393",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "On October 8, 2013, riociguat (Adempas\u00ae) became the first medication approved for multiple etiologies of PH.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24524094",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Duavee, an oral contraceptive; riociguat (Adempas) for two types of pulmonary hypertension; and macitentan (Opsumit) for pulmonary arterial hypertension.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24391396",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Riociguat (Adempas(\u00ae)), an oral first-in-class soluble guanylate cyclase (sGC) stimulator, is under global development by Bayer Healthcare Pharmaceuticals Inc. for the treatment of adult patients with inoperable or chronic/persistent chronic thromboembolic pulmonary hypertension (CTEPH) and for the treatment of adult patients with pulmonary arterial hypertension (PAH). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24218053",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Riociguat (Adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25395817",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Riociguat (Adempas(\u00ae)), an oral first-in-class soluble guanylate cyclase (sGC) stimulator, is under global development by Bayer Healthcare Pharmaceuticals Inc",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24218053",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Duavee, an oral contraceptive; riociguat (Adempas) for two types of pulmonary hypertension; and macitentan (Opsumit) for pulmonary arterial hypertension",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24391396",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "riociguat"
}